Global & Regional Health Technology Assessment

Skip to main content Skip to main navigation menu Skip to site footer

Current Issue

Vol 7 No 1 (2020): January 2020

Published: 2020-07-15

Original Research Article

A cost-minimization analysis of a preventive testing strategy for relatives of patients with BRCA mutated ovarian cancer

Eugenio Di Brino, Matteo Ruggeri, Stefania Boccia, Nicoletta Cerana, Domenica Lorusso, Dario Sacchini, Antonella Savarese, Liliana Varesco, Americo Cicchetti

1-8
- PDF
- ePub
- html
Evaluation of the use of Floseal®, a topical hemostatic agent, in cardiothoracic surgery

Rossella Di Bidino, Luz Irene Urbina, Marco Oradei, Amerigo Cicchetti

14-25
- PDF
- ePub
- html
Valorization of clinical trials from the Italian National Health Service perspective: definition and first application of a model to estimate avoided costs

Americo Cicchetti, Domenico Addesso, Filippo Elvino Leone, Antonino Amato, Luca Angerame, Angelo D'Aversa, Mario Fraticelli, Carlo Nicora, Eleonora Sfreddo, Mariangela Fumarola, Roberta Porcino, Gabriella Cocciolo, Simona Re, Sergio Scaccabarozzi

26-32
- PDF
- ePub
- html
The effects of disease cross-coverage by dupilumab on the costs sustained by the Italian National Health Service

Claudio Jommi, Filippo Cipriani, Francesca Fanelli, Maria Paola Pedone, Walter Canonica

33-39
- PDF
- ePub
- html
Budget impact analysis of extended half-life recombinant factor IX (rFIXFc) in the treatment of haemophilia B

Andrea Aiello, Maria Elisa Mancuso, Alessio Colombo, Cristina Teruzzi, Patrizia Berto

40-49
- PDF
- ePub
- html
Multidisciplinary approach to psoriasis in the Spanish National Health System: A social return on investment study

Gregorio Carretero, David Moreno, Almudena González Domínguez, David Trigos, Albert Ledesma, Esther Sarquella, María Merino, Carles Blanch, SROI Psoriasis Group

50-56
- PDF
- ePub
- html
Analisi costo-utilità di dupilumab per il trattamento della dermatite atopica grave negli adulti in Italia Cost-effectiveness analysis of dupilumab for the treatment of severe atopic dermatitis in adults in Italy

Antonio Costanzo, Gianluca Furneri, Rossella Bitonti, Maria Paola Pedone, Francesca Fanelli, Roberta Di Turi

57-65
- PDF
- ePub
- html
Patterns of prescription, hospitalizations and costs of herpes zoster in patients at risk, from a large Italian claims database

Silvia Calabria, Giulia Ronconi, Letizia Dondi, Carlo Piccinni, Antonella Pedrini, Immacolata Esposito, Pierluigi Viale, Nello Martini

66-71
- PDF
- ePub
- html
Budget Impact Analysis of anakinra in the treatment of patients with Still’s Disease Analisi di budget impact di anakinra nel trattamento della Malattia di Still in Italia

Roberto Ravasio, Roberto Giacomelli, Stefano Bianchi

72-90
- PDF
- ePub
- html
Costo-utilità di dalbavancina versus standard of care (SoC) in pazienti con ABSSSI non severa in Italia Cost-utility of dalbavancin in patients with non-severe ABSSSI in Italy

Andrea Marcellusi, Chiara Bini, Maria Assunta Rotundo, Rosario Cultrera, Francesco Saverio Mennini

92-100
- PDF
- ePub
- html

Point of View

Value-based healthcare: Il nuovo approccio di AIFA alla determinazione multidimensionale del valore AIFA’s new approach to multidimensional value determination

Oriana Ciani, Carlo Federici, Giulia Fornaro, Carla Rognoni

9-13
- PDF
- ePub
- html

Erratum

Erratum in: Budget Impact Analysis of anakinra in the treatment of patients with Still’s Disease

91
- PDF
- ePub
- html

View All Issues